The International Society for Pharmacoeconomics and Outcomes Research

Models Show Switch to Bevacizumab, Rituximab Biosimilars Yields Millions in Savings

May 25, 2020

Article

Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from 2 studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.

Examining the Links Among Diabetes Education, Activity, and Food Insecurity

May 24, 2020

Article

The presentation at Virtual ISPOR 2020 found that 7% of a group of Medicare beneficiaries with type 2 diabetes was experiencing food insecurity, a rate the lead author found "alarming."

Care Not in Line With Guidelines for HER2-Negative MBC Has Worse Outcomes in Elderly Women

May 23, 2020

Article

More than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, and that was linked to higher mortality as well as higher Medicare costs.

MS Spending Spiked Over the Past Decade as Costly DMTs Emerged, Reports at ISPOR Show

May 23, 2020

Article

A new report shows just how much disease modifying therapies (DMTs) have changed the economic landscape of treating multiple sclerosis.

What Innovations Can Improve Detection of Predictors, Severity in Parkinson Disease?

May 22, 2020

Article

Presented at Virtual ISPOR 2020, researchers examined the efficacy of a machine learning approach in detecting predictors of Parkinson disease (PD), with an additional study testing the use of a statistical model to predict severity of PD.

Discontinuation Rates Matter When Evaluating Biologics in RA, Analysis Finds

May 22, 2020

Article

Incremental cost-effectiveness ratios (ICERs) must be updated to reflect the fact that some patients discontinue biologics and swap in other products, the authors concluded.

Early Detection Programs May Help Offset Costs of COPD Exacerbations, Studies Find

May 21, 2020

Article

Exacerbations of patients with chronic obstructive pulmonary disorder (COPD) can be costly if they are frequent, and early detection programs for COPD may help offset these costs, according to research from 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.

Studies Outline Asthma's Economic Toll

May 21, 2020

Article

Although the total cost of asthma was more than $80 billion in 2013, the expansion of Medicaid in 2014 aided patients with asthma, according to 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.

Opioid Use, Economic Burdens of Migraine Detailed in Pair of Studies at ISPOR

May 20, 2020

Article

At the Virtual ISPOR 2020 conference, researchers presented data on treatment patterns, inpatient and outpatient visits, and pharmacy costs incurred by migraineurs.

What Happens to Patients in the First Year After ILD Diagnosis?

May 20, 2020

Article

Two studies presented at the Virtual 2020 ISPOR conference examined health care resource utilization and health-related quality of life in interstitial lung disease.